What is LTBI Prophylaxis?
LTBI prophylaxis (now more accurately termed "treatment of latent tuberculosis infection") is the administration of antimicrobial therapy to individuals infected with Mycobacterium tuberculosis who have no clinical evidence of active disease, with the goal of preventing progression to active tuberculosis disease. 1
Definition and Purpose
Latent tuberculosis infection (LTBI) represents a state where viable M. tuberculosis bacilli persist in an individual without causing symptoms or signs of active disease 2. These individuals:
- Are asymptomatic
- Have negative chest radiographs
- Cannot transmit tuberculosis to others
- Face a 5-10% lifetime risk of progressing to active TB disease if untreated 1
Treatment of LTBI is highly effective at preventing this progression and accounts for approximately 80% of U.S. TB disease cases, making it a cornerstone of tuberculosis elimination strategy 1.
Current Recommended Treatment Regimens (2020 Guidelines)
The NTCA/CDC 2020 guidelines establish three preferred rifamycin-based regimens based on superior effectiveness, safety, and treatment completion rates 1:
Preferred Regimens:
- 3 months of once-weekly isoniazid plus rifapentine (3HP)
- 4 months of daily rifampin (4R)
- 3 months of daily isoniazid plus rifampin (3HR)
Alternative Regimens:
- 6 months of daily isoniazid (6H) - for patients unable to take rifamycin-based regimens
- 9 months of daily isoniazid (9H) - may offer slightly better efficacy but with higher toxicity risk and lower completion rates 1
Critical caveat: Rifampin and rifapentine are NOT interchangeable drugs despite similar names—prescribers must ensure patients receive the correct medication for the intended regimen 1.
Key Clinical Considerations
Who Should Receive Treatment:
The decision to treat LTBI focuses on individuals at increased risk for progression to active disease, including:
- Recent contacts of infectious TB cases
- Persons with HIV infection (where benefit is most pronounced with positive tuberculin skin test) 3
- Individuals on immunosuppressive therapy (TNF-α inhibitors, biologics, corticosteroids) 4, 5, 6
- Those with radiographic evidence of prior TB (healed lesions)
- Recent converters (tuberculin skin test or IGRA)
Absolute Requirement Before Treatment:
Active tuberculosis disease MUST be ruled out before initiating LTBI treatment 7. This requires:
- Symptom assessment
- Chest radiography
- Microbiological evaluation if any suspicion exists
Drug Resistance Considerations:
These guidelines apply ONLY to presumed drug-susceptible M. tuberculosis 1. When the source case has documented multidrug-resistant TB (resistant to both isoniazid and rifampin), different treatment approaches are required.
Evolution of Terminology
The term has evolved from "chemoprophylaxis" or "preventive therapy" to "treatment of LTBI" to more accurately reflect that this addresses an existing infection rather than preventing one 2, 7, 8.
Why Shorter Rifamycin-Based Regimens Are Preferred
The 2020 guidelines represent a paradigm shift based on GRADE methodology and network meta-analysis 1:
- Higher completion rates with 3-4 month regimens versus 6-9 month isoniazid
- Similar or superior effectiveness
- Lower hepatotoxicity risk compared to longer isoniazid monotherapy
- Better real-world adherence, which translates to greater population-level effectiveness 1
Common Pitfalls to Avoid
- Confusing rifampin with rifapentine - these require different dosing schedules and are not substitutable
- Failing to rule out active TB before starting treatment
- Not considering drug-drug interactions with rifamycins (particularly in patients on antiretrovirals, immunosuppressants, or other medications)
- Using 2 months of rifampin plus pyrazinamide - this regimen is explicitly NOT recommended due to severe hepatotoxicity risk 1
- Inadequate monitoring during treatment for emergence of active TB symptoms 7